Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Celiac Disease: HELP
Articles by Isha Singh
Based on 2 articles published since 2010
(Why 2 articles?)
||||

Between 2010 and 2020, I. Singh wrote the following 2 articles about Celiac Disease.
 
+ Citations + Abstracts
1 Article Patients with celiac disease may have normal weight or may even be overweight. 2016

Singh, Isha / Agnihotri, Abhishek / Sharma, Aishwairya / Verma, Anil K / Das, Prasenjit / Thakur, Bhaskar / Sreenivas, V / Gupta, Siddhartha Datta / Ahuja, Vineet / Makharia, Govind K. ·Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110 029, India. · Department of Pathology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110 029, India. · Department of Biostatistics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110 029, India. · Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110 029, India. govindmakharia@gmail.com. ·Indian J Gastroenterol · Pubmed #26892766.

ABSTRACT: BACKGROUND: It is believed that patients with celiac disease (CeD) are likely to be underweight. Data from west suggest that 8% to 40% of them can be overweight or obese. We reviewed data on body mass index (BMI) of our patients with CeD and derived the correlations between BMI and other disease characteristics. METHODS: We retrospectively studied case records of 210 adolescent and adult patients with CeD at the Celiac Disease Clinic. We classified BMI as underweight, normal weight, overweight, and obese based on the Consensus Statement for Diagnosis of Obesity, Abdominal Obesity and the Metabolic Syndrome for Asian Indians for those with age >18 years and revised Indian Association of Pediatrics BMI-for-age charts for those between 12 and 18 years. RESULTS: Of 210 patients, 76 (36.2%) were underweight, 115 (54.8%) were normal weight, 13 (6.2%) were overweight, and 6 (2.9%) were obese. There was no difference in the proportion of underweight between male and female patients with CeD. The mean age of underweight patients was similar to those having normal or overweight. There was no difference in the mean duration of symptoms; frequencies of diarrhea, anorexia, and weakness; anemia; titer of anti-tissue transglutaminase antibody; and severity of villous atrophy in those with underweight or normal weight or overweight. CONCLUSIONS: In our practice, only one third of patients with CeD had low BMI. A diagnosis of CeD should not be excluded if patient has normal or high BMI.

2 Article Immunopathogenesis of olmesartan-associated enteropathy. 2015

Marietta, E V / Nadeau, A M / Cartee, A K / Singh, I / Rishi, A / Choung, R S / Wu, T-T / Rubio-Tapia, A / Murray, J A. ·Department of Immunology, Mayo Clinic, Rochester, MN, USA. · Department of Dermatology, Mayo Clinic, Rochester, MN, USA. · Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. · Department of Anatomic Pathology, Mayo Clinic, Rochester, MN, USA. ·Aliment Pharmacol Ther · Pubmed #26423313.

ABSTRACT: BACKGROUND: Olmesartan-associated enteropathy (OAE) is characterised by diarrhoea, nausea, vomiting, abdominal pain, weight loss and severe sprue-like enteropathy, all of which are resolved after discontinuation of olmesartan medoximil. AIM: To determine the mechanistic similarities of OAE with coeliac sprue. METHODS: Duodenal biopsies were extracted from OAE patients before (n = 11) or after (n = 17) discontinuation of olmesartan medoxomil (on or off olmesartan medoxomil). There were seven 'on/off' paired samples. Formalin-fixed biopsies were stained for CD8, CD4, FoxP3, IL-15R and psmad 2/3. Caco2 cells (human colonic epithelial line) were treated with olmesartan medoxomil and stained for IL-15, IL-15R and ZO-1. RESULTS: In the 'on olmesartan medoxomil' duodenal biopsies, a significant increase in the numbers of CD8+ cells and the number of cells that are FoxP3+ (a regulatory T-cell marker) are present in the duodenum as compared to the duodenal biopsies from patients who discontinued olmesartan medoxomil. IL15R expression is also increased with olmesartan medoxomil use. Evaluation of the effect of olmesartan medoxomil upon Caco-2 cells demonstrated that IL15 expression is increased in response to olmesartan medoxomil treatment. Further, ZO-1, a tight junction protein, is disrupted in olmesartan medoxomil-treated Caco-2 cells. CONCLUSIONS: Olmesartan-associated enteropathy shares many features with coeliac disease, including symptoms and immunopathogenic pathways, such as increased numbers of CD8+ cells and corresponding overexpression of IL15 by epithelial cells. Taken together, the treatment of epithelial cells with olmesartan medoxomil induces a response by intestinal epithelial cells that is similar to the innate effects of gluten upon the epithelium of coeliac patients.